News | July 26, 2021
Panacea Biotec posts consolidated loss of Rs. 57.35 Cr in Q1FY22
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has reported total income of Rs.45.29 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
